Skip to main content
TipRanks
Go Ultimate75% OFF

Henry Schein (HSIC) AI Stock Analysis

420 Followers
HSIC

Henry Schein

(NASDAQ:HSIC)

Select Model
Rating:64Neutral
Price Target:$88.00▲(3.58% Upside)
Action:reiterated
Date:11/04/26

HSIC scores as moderately attractive, led by strong earnings-call momentum (raised EPS guidance, margin expansion, share gains, and confidence in cash flow) and generally steady operating performance. The score is held back by increased balance-sheet leverage and weakening recent free-cash-flow trend, while technical indicators are currently bearish and valuation (P/E ~23.8) does not look meaningfully discounted without dividend support.

Positive Factors
Dental share gainsStrong U.S. dental merchandise growth reflects volume gains and expanding customer penetration in a stable market. Increasing share among private practices and emerging DSOs, alongside greater share of wallet, supports durable revenue growth and reinforces Henry Schein’s distribution position.
Negative Factors
Higher leverageThe substantial increase in leverage reduces financial flexibility compared with prior years and makes the business more sensitive to interest costs or operating setbacks. It may also constrain the capacity to fund acquisitions, repurchases, and growth initiatives internally.

Henry Schein Key Performance Indicators (KPIs)

Operating Income by SegmentShows how profitable each major business line is after operating costs, highlighting which segments drive earnings, where margins are under pressure, and how efficiently management converts sales into profit.

-$200.00M-$100.00M$0.00$100.00M$200.00M$300.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

A 2024 reporting recast shuffled profits out of legacy Healthcare/Tech lines into new Global Distribution, Speciality Products and Global Technology segments, while large negative “Adjustments” and a growing Corporate drag reflect restructuring, remeasurement and other one‑offs that depress GAAP operating income. Management’s guidance raise and $200M+ value‑creation plan suggest the underlying global segments are expanding margins and driving real profitability, but investors should watch the pace of adjustment reversals and Corporate G&A to see how much of the improvement converts to GAAP results.

Data provided by:The Fly

Henry Schein (HSIC) vs. SPDR S&P 500 ETF (SPY)

-5%0%5%10%15%20%25%30%HSIC+19.36%SPY+12.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$9.39B
Dividend Yield
―
Average Volume (3M)
1.28M
Price to Earnings (P/E)
22.9
Beta (1Y)
0.32
Revenue Growth
6.15%
EPS Growth
15.68%
Country
US
Employees
25,000
Sector
Healthcare
Sector Strength
51
Industry
Medical - Distribution

Henry Schein Business Overview & Revenue Model

Company Description

Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services. The company caters to a diverse clientele across the globe, including dental professionals and laboratories, physician practices, go...

How the Company Makes Money

Henry Schein makes money primarily by selling and distributing healthcare products and practice-related solutions to professional customers. A large portion of revenue comes from ongoing, repeat purchases of consumable supplies used in routine patien...

Henry Schein Earnings Call Summary

Earnings Call Date:Nov 03, 2026(Q3-2026)|% Change Since:-1.92%|Next Earnings Date:Mar 02, 2027
Earnings Call SentimentPositive

The call was strongly positive. Highlights significantly outweighed the challenges, with 8.6% U.S. dental merchandise growth driven primarily by volume and share gains, 19.1% underlying adjusted EPS growth, margin expansion, strong cash flow, ongoing value-creation benefits, raised EPS guidance, and continued technology and home-solutions growth. The company acknowledged pressure in discretionary dental procedures, lower point-of-care diagnostic and vaccine demand, a Brazil headwind, restructuring costs, and the nonrecurring nature of the tariff refund benefit, but management said these issues do not materially alter current growth expectations.

Positive Updates

Strong U.S. Dental Merchandise Growth and Share Gains
U.S. dental merchandise sales grew 8.6%, including 7% internal local-currency growth, driven primarily by volume in a stable market. Management said growth was especially strong among private practices and emerging DSOs, reflecting market-share gains, increased active customers, greater share of wallet, and growth in company-owned and exclusive products.

Negative Updates

Pressure in Discretionary Dental Procedures
Management reported some pressure in discretionary procedures because patients may be more selective about out-of-pocket costs and may defer treatments. The company said these procedures represent a relatively limited portion of its portfolio and do not materially affect current growth expectations.

Company Guidance

Henry Schein’s 2026 total sales growth expectations remain unchanged at 4.5 to 5.5 percent over 2025, while 2026 non GAAP diluted EPS attributable to Henry Schein, Inc. is now expected to be $5.50 to $5.56, compared to prior guidance of $5.29 to $5.39, and 2026 adjusted EBITDA is expected to grow in the high single digits versus 2025 adjusted EBITDA of $1.1 billion; the guidance assumes no significant additional tariff refunds or remeasurement gains for the remainder of 2026, foreign currency exchange rates will remain generally consistent with current levels, and an estimated non GAAP effective tax rate of approximately 24%. The company continues to expect more than $200 million of operating income improvement, including a $125 million run rate by the end of 2026, and operating cash flow to exceed net income for the full year; management expects double digit EPS growth for the full year of 2026 and expressed confidence in achieving double-digit earnings growth in 2027, with targeted and limited growth investments in the fourth quarter contributing to growth in 2027, expects fourth quarter technology sales growth to be in line with the first half of this year, expects U. S. Dental equipment growth to continue in the fourth quarter, and expects an early 2027 US flu season to support better medical growth in Q4.

Henry Schein Financial Statement Overview

Summary

Income statement trends are steady (TTM revenue up vs prior year; stable operating profitability), but net margins are relatively thin (~3%) versus earlier years. The main drag is balance-sheet leverage rising materially (debt ~1.21x equity), reducing flexibility, while cash flow remains positive but has weakened recently (TTM free cash flow down vs prior period and only moderate debt coverage).

Income Statement

72Positive

Balance Sheet

55Neutral

Cash Flow

61Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue13.73B13.18B12.67B12.34B12.65B12.40B
Gross Profit4.20B3.84B3.77B3.65B3.65B3.67B
EBITDA1.09B1.01B912.00M851.00M977.00M1.07B
Net Income421.00M398.00M390.00M416.00M538.00M623.91M
Balance Sheet
Total Assets11.51B11.21B10.22B10.57B8.61B8.48B
Cash, Cash Equivalents and Short-Term Investments184.00M156.00M122.00M171.00M117.00M118.00M
Total Debt3.89B3.69B2.87B2.74B1.50B1.22B
Total Liabilities6.78B6.42B5.38B5.42B3.94B3.81B
Stockholders Equity3.16B3.25B3.39B3.65B3.45B3.42B
Cash Flow
Free Cash Flow529.00M573.00M661.00M313.00M506.00M630.57M
Operating Cash Flow687.00M712.00M848.00M500.00M602.00M709.58M
Investing Cash Flow-318.00M-477.00M-430.00M-1.14B-276.00M-677.22M
Financing Cash Flow-346.00M-111.00M-510.00M701.00M-315.00M-332.96M

Henry Schein Technical Analysis

Technical Analysis SentimentNegative
Last Price84.96

Price Trends

50DMA85.81Negative
100DMA86.62Negative
200DMA81.57Positive

Market Momentum

MACD0.26Negative
RSI47.00Neutral
STOCH49.40Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HSIC, the sentiment is Negative. The current price of 84.96 is below the 20-day moving average (MA) of 85.87, below the 50-day MA of 85.81, and above the 200-day MA of 81.57, indicating a neutral trend. The MACD of 0.26 indicates Negative momentum. The RSI at 47.00 is Neutral, neither overbought nor oversold. The STOCH value of 49.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HSIC.

Henry Schein Risk Analysis

Henry Schein disclosed 29 risk factors in its most recent earnings report. Henry Schein reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Our business could be affected by activist investors.Q4, 2024
2.We may be unsuccessful in achieving our strategic growth objectives.Q4, 2024
3.Our business could be affected by the recently signed Strategic Partnership Agreement.Q4, 2024

Henry Schein Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HSIC against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
CAHCAH73Outperform$65.61B36.58-62.56%0.72%10.00%16.74%
HSICHSIC64Neutral$9.39B22.8813.13%―6.15%15.68%
MCKMCK64Neutral$127.58B28.38-161.18%0.31%8.19%21.01%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
YIYI40Underperform$24.95M-1.5723.64%―-23.90%-45.45%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%HSICCAHMCKAHGYIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HSIC and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HSICHenry Schein84.9614.3620.34%
CAHCardinal Health283.8578.2738.07%
MCKMcKesson Corporation1105.04255.9130.14%
AHGAkso Health Group Sponsored ADR1.33-0.20-13.07%
YI111, Inc.2.84-0.96-25.26%

Henry Schein Corporate Events

Business Operations and StrategyExecutive/Board Changes

Henry Schein Announces CFO Transition and Leadership Enhancements

Positive
Oct 8, 2026

Henry Schein, Inc. is a products, services, and technology platforms company focused on healthcare customers, supplying office-based dental and medical practitioners, dental laboratories, and institutional and government clinics with more than 300,00...

Business Operations and StrategyPrivate Placements and Financing

Henry Schein Expands and Extends Revolving Credit Facility

Positive
Sep 22, 2026

On September 21, 2026, Henry Schein amended and restated its revolving credit agreement, expanding the aggregate commitments from $1 billion to $1.25 billion and extending the facility’s termination date to September 19, 2031. The revised facility, a...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 04, 2026